Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed May 7, 2012 · 10-Q · 37 days after period end · 0001193125-12-215311
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $7.44M | $7.54M |
| Net Income | -$15.12M | -$9.64M |
| EPS Diluted | -$0.14 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
ended Mar 31, 2012 · filed May 7, 2012 · 37 d after period end
